Cited by 755Malaria Research and ControlBacterial Infections and VaccinesTravel-related health issues

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Open access

The RTS,S Clinical Trials Partnership·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1208394PMC PMC10915853

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial. METHODS: We administered RTS,S/AS01 or a comparator vaccine to 6537 infants who were 6 to 12 weeks of age at the time of the first vaccination in conjunction with Expanded Program on Immunization (EPI) vaccines in a three-dose monthly schedule. Vaccine efficacy against the first or only episode of clinical malaria during the 12 months after vaccination, a coprimary end point, was analyzed with the use of Cox regression. Vaccine efficacy against all malaria episodes, vaccine efficacy against severe malaria, safety, and immunogenicity were also assessed. RESULTS: The incidence of the first or only episode of clinical malaria in the intention-to-treat population during the 14 months after the first dose of vaccine was 0.31 per person-year in the RTS,S/AS01 group and 0.40 per person-year in the control group, for a vaccine efficacy of 30.1% (95% confidence interval [CI], 23.6 to 36.1). Vaccine efficacy in the per-protocol population was 31.3% (97.5% CI, 23.6 to 38.3). Vaccine efficacy against severe malaria was 26.0% (95% CI, -7.4 to 48.6) in the intention-to-treat population and 36.6% (95% CI, 4.6 to 57.7) in the per-protocol population. Serious adverse events occurred with a similar frequency in the two study groups. One month after administration of the third dose of RTS,S/AS01, 99.7% of children were positive for anti-circumsporozoite antibodies, with a geometric mean titer of 209 EU per milliliter (95% CI, 197 to 222). CONCLUSIONS: The RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants. (Funded by GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative; RTS,S ClinicalTrials.gov number, NCT00866619.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1208394

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Self-citation
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
Bhuiyan, P. S., & Rege, N. N. (2001) · PubMed · Cited by 527
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants
Siegrist, C. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00342-6 · Cited by 350
Design and Analysis of Vaccine Studies
Halloran, M. E., Longini, I. M., & Struchiner, C. J. (2009) · Statistics for biology and health · doi:10.1007/978-0-387-68636-3 · Cited by 332
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial
Aponte, J. J., Aide, P., Renom, M., Mandomando, I., Bassat, Q., Sacarlal, J., Manaca, M. N., Lafuente, S., Barbosa, A., Leach, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61542-6 · Cited by 279
Glycoconjugate vaccines and immune interference: A review
Dagan, R., POOLMAN, J. T., & Siegrist, C. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.026 · Cited by 270
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
Abdulla, S., Oberholzer, R., Juma, O. A., Kubhoja, S. D., Machera, F., Membi, C. D., Omari, S., Urassa, A., Mshinda, H., Jumanne, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807773 · Cited by 239

Flagged first, then by citations

Show all 31 references

1 of the 31 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Brabin B, 1990, Trop Dis Bull, 87, R1

Sorted by citations

Items 401–500 of 755

Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers
von Seidlein, L., Hanboonkunupakarn, B., Jittamala, P., Pongsuwan, P., Chotivanich, K., Tärning, J., Hoglund, R. M., Winterberg, M., Mukaka, M., Peerawaranun, P., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1643675 · Cited by 17
Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha
Wetzel, D., Chan, J.-A., Suckow, M., Barbian, A., Weniger, M., Jenzelewski, V., Reiling, L., Richards, J. S., Anderson, D. A., Kouskousis, B. P., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221394 · Cited by 16
El desarrollo de nuevas vacunas
González‐Romo, F., & Picazo, J. J. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.06.013 · Cited by 15
Operational Research Needs Toward Malaria Elimination in China
Chen, S., Ju, C., Chen, J., Zheng, B., Huang, F. J., Xiao, N., Zhou, X., Ernest, T., & Zhou, X. (2014) · Advances in Parasitology/Advances in parasitology · doi:10.1016/b978-0-12-800869-0.00005-6 · Cited by 15
The potential role of Ziziphus spina-christi leaf extracts against Plasmodium berghei-induced liver and spleen injury
Hafiz, T. A., & Mubaraki, M. A. (2016) · Biomedical Research-tokyo · Cited by 15
Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design
Ord, R. L., Rodriguez, M., & Lobo, C. A. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1026496 · Cited by 16
“Omics” in the study of the major parasitic diseases malaria and schistosomiasis
de Sousa, T. N., Menezes‐Neto, A., & de Brito, C. F. A. (2013) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2013.07.008 · Cited by 15
Assessment of the RTS,S/AS01 malaria vaccine
Moorthy, V., Rd, N., DUCLOS, P. J., Okwo‐Bele, J., & Smith, P. G. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70047-1 · Cited by 15
Plant expression and characterization of the transmission-blocking vaccine candidate PfGAP50
Beiss, V., Spiegel, H., Boes, A., Scheuermayer, M., Reimann, A., Schillberg, S., & Fischer, R. (2015) · BMC Biotechnology · doi:10.1186/s12896-015-0225-x · Cited by 15
Adaptation of the [ 3 H]Hypoxanthine Uptake Assay for In Vitro -Cultured Plasmodium knowlesi Malaria Parasites
Arnold, M. S. J., Engel, J. A., Chua, M. J., Fisher, G. M., Skinner‐Adams, T. S., & Andrews, K. T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02948-15 · Cited by 15
Ameliorative role of Ziziphus spina-christi leaf extracts against hepatic injury induced by Plasmodium chabaudi infected erythrocytes
Hafiz, T. A., Mubaraki, M. A., Diab, M. S. M., Dkhil, M. A., & Al‐Quraishy, S. (2017) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2017.10.012 · Cited by 15
Chimeric Murine Polyomavirus Virus-Like Particles Induce Plasmodium Antigen-Specific CD8+ T Cell and Antibody Responses
Pattinson, D. J., Apte, S., Wibowo, N., Chuan, Y., Rivera-Hernández, T., Groves, P., Lua, L., Middelberg, A., & Doolan, D. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00215 · Cited by 13
A chemokine-fusion vaccine targeting immature dendritic cells elicits elevated antibody responses to malaria sporozoites in infant macaques
Luo, K., Gordy, J. T., Zavala, F. P., & Markham, R. B. (2021) · Scientific Reports · doi:10.1038/s41598-020-79427-3 · Cited by 18
Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines
Fowkes, F. J. I., Simpson, J. A., & Beeson, J. G. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-232 · Cited by 14
Final results from a pivotal phase 3 malaria vaccine trial
Moorthy, V., & Okwo-Bele, J.-M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60767-x · Cited by 14
The history of the RTS,S/AS01 malaria vaccine trial
Keating, C. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30815-1 · Cited by 14
RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial
Suau, R., Vidal, M., Aguilar, R., Ruiz‐Olalla, G., Vázquez-Santiago, M., Jairoce, C., Nhabomba, A. J., Gyan, B. A., Dosoo, D., Asante, K. P., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.12.038 · Cited by 17
A Mosquito AgTRIO Monoclonal Antibody Reduces Early Plasmodium Infection of Mice
Chuang, Y.-M., Tang, X.-D., & Fikrig, E. (2021) · Infection and Immunity · doi:10.1128/iai.00359-21 · Cited by 13
Malaria Vaccine Development: Focusing Field Erythrocyte Invasion Studies on Phenotypic Diversity
Ahouidi, A. D., Amambua‐Ngwa, A., Awandare, G. A., Bei, A. K., Conway, D. J., Diakité, M., Duraisingh, M. T., Rayner, J. C., & Ζήνωνος, Ζ. (2015) · Trends in Parasitology · doi:10.1016/j.pt.2015.11.009 · Cited by 14
Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model
Mizutani, M., Fukumoto, S., Soubeiga, A. P., Soga, A., Iyori, M., & Yoshida, S. (2016) · Malaria Journal · doi:10.1186/s12936-016-1297-3 · Cited by 16
Clinical laboratory reference values amongst children aged 4 weeks to 17 months in Kilifi, Kenya: A cross sectional observational study
Gitaka, J., Ogwang, C., Ngari, M. M., Akoo, P., Olotu, A., Kerubo, C., Fegan, G., Njuguna, P., Nyakaya, G., Otieno, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177382 · Cited by 14
Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen
Witte, D., Cunliffe, N. A., Turner, A., Ngulube, E., Ofori‐Anyinam, O., Vekemans, J., Chimpeni, P., Lievens, M., Wilson, T. P., Njirammadzi, J., et al. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000001937 · Cited by 14
Developing effective vaccines: Cues from natural infection
Bhurani, V., Mohankrishnan, A., Morrot, A., & Dalai, S. K. (2018) · International Reviews of Immunology · doi:10.1080/08830185.2018.1471479 · Cited by 17
A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01E on blood stage immunity in young Kenyan children
Ndungu, F. M., Mwacharo, J., Wambua, J., Njuguna, P., Marsh, K., DRAKELEY, C. J., & Bejon, P. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15002.1 · Cited by 13
Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine
MacMillen, Z., Hatzakis, K., Simpson, A., Shears, M. J., Watson, F., Erasmus, J. H., Khandhar, A. P., Wilder, B. K., Murphy, S. C., Reed, S. G., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00799-4 · Cited by 12
Vaccines today, vaccines tomorrow: a perspective
Loucq, C. (2013) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2013.2.1.4 · Cited by 12
A Replicating Adenovirus Capsid Display Recombinant Elicits Antibodies against Plasmodium falciparum Sporozoites in Aotus nancymaae Monkeys
Karen, K. A., Deal, C. E., Adams, R. J., Nielsen, C. M., Ward, C., Espinosa, D. A., Xie, J., Zavala, F. P., & Ketner, G. W. (2014) · Infection and Immunity · doi:10.1128/iai.02626-14 · Cited by 13
Drug Target Validation Methods in Malaria - Protein Interference Assay (PIA) as a Tool for Highly Specific Drug Target Validation
Meissner, K. A., Lunev, S., Wang, Y., Linzke, M., Batista, F. D. A., Wrenger, C., & Groves, M. R. (2016) · Current Drug Targets · doi:10.2174/1389450117666160201115003 · Cited by 13
Route of administration of attenuated sporozoites is instrumental in rendering immunity against Plasmodia infection
Parmar, R., Patel, H., Yadav, N., Patidar, M., Tyagi, R. K., & Dalai, S. K. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.095 · Cited by 13
Identification of a Novel CD8 T Cell Epitope Derived from Plasmodium berghei Protective Liver-Stage Antigen
Pichugin, A. V., Zarling, S., Perazzo, L., Duffy, P. E., Ploegh, H. L., & Krzych, U. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00091 · Cited by 13
Meeting report: WHO consultation on malaria vaccine development, Geneva, 15–16 July 2019
Vekemans, J., Schellenberg, D. M., Benns, S., O’Brien, K. L., & Alonso, P. L. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.093 · Cited by 13
Plasmodium vivax Antigen Discovery Based on Alpha-Helical Coiled Coil Protein Motif
Céspedes, N., Habel, C., Lopez-Perez, M., Castellanos, A., Kajava, A. V., Servis, C., Felger, I., Moret, R., Arévalo‐Herrera, M., Corradin, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100440 · Cited by 13
Effect of malaria transmission reduction by insecticide-treated bed nets (ITNs) on the genetic diversity of Plasmodium falciparum merozoite surface protein (MSP-1) and circumsporozoite (CSP) in western Kenya
Kariuki, S., Njunge, J. M., Muia, A., Muluvi, G., Gatei, W., ter Kuile, F. O., Terlouw, D. J., Hawley, W. A., Phillips‐Howard, P. A., Nahlen, B. L., et al. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-295 · Cited by 13
Synergistic and antagonistic interactions between bednets and vaccines in the control of malaria
Artzy‐Randrup, Y., Dobson, A. P., & Pascual, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409467112 · Cited by 12
School-Based Malaria Screening and Treatment Reduces Plasmodium falciparum Infection and Anemia Prevalence in Two Transmission Settings in Malawi
Cohee, L. M., Peterson, I., Buchwald, A. G., Coalson, J. E., Valim, C., Chilombe, M., Ngwira, A., Bauleni, A., Schaffer-DeRoo, S., Seydel, K. B., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac097 · Cited by 13
The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial
Macià, D., Campo, J. J., Jairoce, C., Mpina, M., Sorgho, H., Dosoo, D., Agnandji, S. T., Kusi, K. A., Molinos-Albert, L. M., Kariuki, S., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00527-9 · Cited by 13
Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and delivery
Ford, A. Q., Touchette, N. A., Hall, B., Hwang, A., & Hombach, J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.038 · Cited by 12
Magnitude, Specificity, and Avidity of Sporozoite-Specific Antibodies Associate With Protection Status and Distinguish Among RTS,S/AS01 Dose Regimens
Dennison, S. M., Reichartz, M., Abraha, M., Spreng, R. L., Wille-Reece, U., Dutta, S., Jongert, E., Alam, S. M., & Tomaras, G. D. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa644 · Cited by 14
Repeated Dose Toxicity Study and Developmental and Reproductive Toxicology Studies of a Respiratory Syncytial Virus Candidate Vaccine in Rabbits and Rats
Stokes, A. H., Franklin, K. M., Fisher, D. E., Posobiec, L. M., Binazon, O., Tripathi, N., Ringenberg, M. A., Charlap, J. H., Ziejewski, M. K., Vemireddi, V., et al. (2021) · International Journal of Toxicology · doi:10.1177/1091581820985782 · Cited by 12
Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
Rausch, K. M., Barnafo, E. K., Lambert, L., Muratova, O. V., Gorres, J. P., Anderson, C., Narum, D. L., Wu, Y., Morrison, R. D., Zaidi, I., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107192 · Cited by 12
Monoclonal antibody applications in travel medicine
de Jong, H. K., & Grobusch, M. P. (2024) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-023-00212-x · Cited by 12
RTS,S malaria vaccine development: progress and considerations for postapproval introduction
Asante, K. P., Adjei, G., Enuameh, Y., & Owusu‐Agyei, S. (2016) · Vaccine Development and Therapy · doi:10.2147/vdt.s53028 · Cited by 12
Monoclonal Antibodies against Plasmodium falciparum Circumsporozoite Protein
Zhang, M., Mandraju, R., Rai, U., Shiratsuchi, T., & Tsuji, M. (2017) · Antibodies · doi:10.3390/antib6030011 · Cited by 12
How can we develop an effective subunit vaccine to achieve successful malaria eradication?
Pirahmadi, S., Afzali, S., Zargar, M., Zakeri, S., & Mehrizi, A. A. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105203 · Cited by 12
Murine infection models for vaccine development
Matuschewski, K. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23218 · Cited by 12
Management strategies in a malaria model combining human and transmission-blocking vaccines
Mohammed-Awel, J., Zhao, R., Numfor, E., & Lenhart, S. (2017) · Discrete and Continuous Dynamical Systems - B · doi:10.3934/dcdsb.2017049 · Cited by 12
Live attenuated pre-erythrocytic malaria vaccines
Keitany, G. J., Vignali, M., & Wang, R. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.972764 · Cited by 16
Genetic variations of Plasmodium falciparum circumsporozoite protein and the impact on interactions with human immunoproteins and malaria vaccine efficacy
Dieng, C. C., Ford, C. T., Lerch, A., Donu, D., Huynh, J., Vegesna, K., Guo, J., Janies, D. A., Amoah, L. E., Afrane, Y. A., et al. (2023) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2023.105418 · Cited by 12
Machine learning prediction of malaria vaccine efficacy based on antibody profiles
Wistuba-Hamprecht, J., Reuter, B., Fendel, R., Hoffman, S. L., Campo, J. J., Felgner, P. L., Kremsner, P. G., Mordmüller, B. G., & Pfeifer, N. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012131 · Cited by 12
Periodic patterns and Pareto efficiency of state dependent impulsive controls regulating interactions between wild and transgenic mosquito populations
Zhang, H., Georgescu, P., & Zhang, L. (2015) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2015.07.013 · Cited by 11
The Development of the Adjuvant System AS01
Didierlaurent, A. M., Berger, A., Heineman, T. C., Henderickx, V., Silva, F. T. D., Vekemans, J., Voss, G., & Garçon, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.00014-1 · Cited by 11
Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of RecombinantPfs25, a Leading Transmission-Blocking Vaccine Candidate
Parzych, E. M., Miura, K., Ramanathan, A. A., Long, C. A., & Burns, J. M. (2017) · Infection and Immunity · doi:10.1128/iai.00486-17 · Cited by 11
Proteomic analysis of Plasmodium falciparum histone deacetylase 1 complex proteins
Engel, J. A., Norris, E. L., Gilson, P. R., Przyborski, J. M., Shonhai, A., Blatch, G. L., Skinner‐Adams, T. S., Gorman, J. J., Headlam, M. J., & Andrews, K. T. (2019) · Experimental Parasitology · doi:10.1016/j.exppara.2019.01.008 · Cited by 14
Severe malaria. Current concepts and practical overview: What every intensivist should know
Mer, M., Dünser, M. W., Giera, R., & Dondorp, A. M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06019-0 · Cited by 11
Cost-effective analysis of childhood malaria vaccination in endemic hotspots of Bangladesh
Sarker, A. R., & Sultana, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233902 · Cited by 11
Non-synonymous amino acid alterations in PfEBA-175 modulate the merozoite ligand's ability to interact with host's Glycophorin A receptor
Chowdhury, P., Ray, S., Chakraborty, A., Sen, S., Dasgupta, A. K., & Sengupta, S. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104418 · Cited by 10
Induction of liver-resident memory T cells and protection at liver-stage malaria by mRNA-containing lipid nanoparticles
Nakamae, S., Miyagawa, S., Ogawa, K., Kamiya, M., Taniguchi, M., Ono, A., Kawaguchi, M., Teklemichael, A. A., Jian, J., Araki, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1116299 · Cited by 11
Bibliometric Analysis of Ghana Publications in the Science Citation Index Expanded
Boamah, P. O., & Ho, Y. (2017) · Revista de Biología Tropical · doi:10.15517/rbt.v66i1.29250 · Cited by 11
Genetic Diversity of the Plasmodium falciparum Glutamate-Rich Protein R2 Region Before and Twelve Years after Introduction of Artemisinin Combination Therapies among Febrile Children in Nigeria
Nguetse, C. N., Ojo, J. A., Nkonganyi, C. N., Ikegbunam, M., Meyer, C. G., Thomas, B. N., Velavan, T. P., & Ojurongbe, O. D. (2018) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.17-0621 · Cited by 11
Mathematical Model for the In-Host Malaria Dynamics Subject to Malaria Vaccines
Orwa, T. O., Mbogo, R. W., & Luboobi, L. S. (2018) · Letters in Biomathematics · doi:10.1080/23737867.2018.1526132 · Cited by 21
Population Attributable Fraction of Anemia Associated with Plasmodium falciparum Infection in Children in Southern Malawi
Yimgang, D. P., Buchwald, A. G., Coalson, J. E., Walldorf, J. A., Bauleni, A., Tembo, A. K., Mathanga, D. P., Taylor, T. E., Laufer, M. K., & Cohee, L. M. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-1120 · Cited by 11
Different regulatory mechanisms in protozoan parasitic infections
Kling, J. C., & Körner, H. (2013) · International Journal for Parasitology · doi:10.1016/j.ijpara.2013.02.001 · Cited by 11
Malaria vaccines: past, present and future
von Seidlein, L., & Bejon, P. (2013) · Archives of Disease in Childhood · doi:10.1136/archdischild-2013-304173 · Cited by 11
High-Density Peptide Arrays for Malaria Vaccine Development
Loeffler, F. F., Pfeil, J., & Heiß, K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_32 · Cited by 12
A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII
Shiratsuchi, T., Rai, U., Kaneko, I., Zhang, M., Iwanaga, S., Yuda, M., & Tsuji, M. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.10.066 · Cited by 11
Th1 immune response to Plasmodium falciparum recombinant thrombospondin‐related adhesive protein (TRAP) antigen is enhanced by TLR3‐specific adjuvant, poly(I:C) in BALB /c mice
Mehrizi, A. A., Torzani, M. A., Zakeri, S., Zadeh, A. J., & Babaeekhou, L. (2018) · Parasite Immunology · doi:10.1111/pim.12538 · Cited by 11
Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development
Krenger, P. S., Roques, M., Vogt, A. S., Pardini, A., Rothen, D. A., Baļķe, I., Schnider, S. T., Mohsen, M. O., Heussler, V. T., Zeltiņš, A., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01006-8 · Cited by 10
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman, N., Tiono, A. B., Bowyer, G., Bellamy, D. G., Stockdale, L. K., Powlson, J., Collins, K. A., Coulibaly, S. A., Datoo, M. S., Silman, D., et al. (2025) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00084-3 · Cited by 13
Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct
Céspedes, N., Jiménez–Charris, E., Lopez-Perez, M., Rubiano, K., Felger, I., Alonso, P. L., Arévalo‐Herrera, M., Corradin, G., & Herrera, S. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.007 · Cited by 10
Adjuvant and Antigen Systems for Malaria Transmission‐Blocking Vaccines
Huang, W., Sia, Z. R., & Lovell, J. F. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800011 · Cited by 10
What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks?
Bartsch, S. M., Asti, L., Cox, S. N., Durham, D. P., Randall, S. L., Hotez, P. J., Galvani, A. P., & Lee, B. Y. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy688 · Cited by 10
Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
Morter, R., Tiono, A. B., Nébié, I., Hague, O., Ouédraogo, A., Diarra, A., Viebig, N. K., Hill, A. V. S., Ewer, K., & Sirima, S. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1058227 · Cited by 10
A human antibody epitope map of the malaria vaccine antigen Pfs25
Shukla, N., Tang, W. K., Coelho, C. H., Long, C. A., Healy, S. A., Sagara, I., Miura, K., Duffy, P. E., & Tolia, N. H. (2023) · npj Vaccines · doi:10.1038/s41541-023-00712-z · Cited by 10
Neonatal infections: A global perspective
Imam, F. B., Darmstadt, G. L., & Zaidi, A. K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00011-1 · Cited by 10
Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation
Faber, B. W., Hellwig, S., Houard, S. A., Havelange, N., Drossard, J., Mertens, H., Croon, A., Kastilan, R., Byrne, R., van der Werff, N., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164053 · Cited by 12
High-Throughput Screening and Prediction Model Building for Novel Hemozoin Inhibitors Using Physicochemical Properties
Huy, N. T., Làn, P. T., Nagai, J., Đăng, T. N., Mbanefo, E. C., Ahmed, A. M., Long, N. P., Le, T., Hung, L. P., Titouna, A., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01607-16 · Cited by 10
A brief history of selected malaria vaccine and medical interventions pursued by the Swiss Tropical and Public Health Institute and partners, 1943-2021
Meier, L., Casagrande, G., Abdulla, S., & Masanja, H. (2021) · Acta Tropica · doi:10.1016/j.actatropica.2021.106115 · Cited by 10
Malaria eradication revisited
Douglas, N. M., Burkot, T. R., & Price, R. N. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab259 · Cited by 12
Structural analysis of Plasmodium falciparum ookinete surface antigen Pfs28 relevant for malaria vaccine design
Shukla, N., Tang, W. K., & Tolia, N. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-24054-3 · Cited by 10
A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum
Radin, K., Clément, F., Jongert, E., Sterckx, Y. G. ‐., Ockenhouse, C. F., Regules, J. A., Lemiale, F., & Leroux-Roels, G. G. (2016) · Malaria Journal · doi:10.1186/s12936-016-1596-8 · Cited by 10
Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations
Excler, J., Saluja, T., Wilder‐Smith, A., Kaminski, R. W., MacLennan, C. A., Cavaleri, M., & Kim, J. H. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127515 · Cited by 9
Efficacy of Phase 3 Trial of RTS, S/AS01 Malaria Vaccine in infants: a systematic review and meta-analysis
Mahmoudi, S., & Keshavarz, H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1271686 · Cited by 9
Retracted
Immunoprofiling Identifies Functional B and T Cell Subsets Induced by an Attenuated Whole Parasite Malaria Vaccine as Correlates of Sterile Immunity
Mura, M., Lu, P., Atre, T., Bolton, J. S., Duncan, E. H., Chaudhury, S., & Bergmann-Leitner, E. S. (2022) · Vaccines · doi:10.3390/vaccines10010124 · Cited by 9
Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and Adults
Belay, W. Y., Kebede, B., Tegegne, B. A., Getachew, M., Abebe, D., Aschale, Y., Belew, H., & Tefera, B. B. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s400155 · Cited by 11
Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model
Genito, C. J., Brooks, K., Smith, A. A., Ryan, E. C., Soto, K., Li, Y., Warter, L., & Dutta, S. (2023) · npj Vaccines · doi:10.1038/s41541-023-00714-x · Cited by 10
Recent Advances in Vaccine Development for the Treatment of Emerging Infectious Diseases
Kumar, S., Thakur, K., Sharma, B., Bhardwaj, T. R., Prasad, D. N., & Singh, R. K. (2019) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.53.3.68 · Cited by 9
Whole-Killed Blood-Stage Vaccine: Is It Worthwhile to Further Develop It to Control Malaria?
Cai, J., Chen, S., Zhu, F., Lu, X., Liu, T., & Xu, W. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.670775 · Cited by 9
Enhanced laboratory capacity development: a boost for effective tuberculosis control in resource-limited settings
Alabi, A. S., Traoré, A. N., Loembé, M. M., Ateba-Ngoa, U., Frank, M., Adégnika, A. A., Lell, B., Mahoumbou, J., Köhler, C., Kremsner, P. G., et al. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.11.404 · Cited by 9
Harnessing liver-resident memory T cells for protection against malaria
Fernandez‐Ruiz, D., de Menezes, M. N., Holz, L. E., Ghilas, S., Heath, W. R., & Beattie, L. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1881485 · Cited by 9
Correlates of protection forPlasmodium falciparummalaria vaccine development: current knowledge and future research
Beeson, J. G., Fowkes, F. J. I., Reiling, L., Osier, F. H. A., Drew, D. R., & Brown, G. V. (2014) · doi:10.2217/fmeb2013.13.144 · Cited by 9
Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection
Schneider, C. G., Fey, J. P., Zou, X., Gerbasi, V. R., Savransky, T., Batt, C. A., Bergmann‐Leitner, E. S., & Angov, E. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.076 · Cited by 8
Display of multiple proteins on engineered canine parvovirus-like particles expressed in cultured silkworm cells and silkworm larvae
Xu, J. C., Sekiguchi, T., Boonyakida, J., Kato, T., & Park, E. Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1096363 · Cited by 8
Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis
Aviraj, K. S., Wasnik, A., Gupta, L., Ranjan, A., & Suresh, H. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02856-6 · Cited by 10
A VAR2CSA:CSP conjugate capable of inducing dual specificity antibody responses
Matondo, S., Thrane, S., Janitzek, C. M., Kavishe, R. A., Mwakalinga, S., Theander, T. G., Salanti, A., Nielsen, M. A., & Sander, A. F. (2017) · African Health Sciences · doi:10.4314/ahs.v17i2.11 · Cited by 9
Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine
Chawla, B., Mahajan, B., Oakley, M. S., Majam, V., Belmonte, A. D., Sedegah, M., Shimp, R. L., Kaslow, D. C., & Kumar, S. (2019) · Infection and Immunity · doi:10.1128/iai.00236-19 · Cited by 8
Chimeric Virus-Like Particles and Capsomeres Induce Similar CD8+ T Cell Responses but Differ in Capacity to Induce CD4+ T Cell Responses and Antibody Responses
Pattinson, D. J., Apte, S. H., Wibowo, N., Rivera-Hernández, T., Groves, P., Middelberg, A. P. J., & Doolan, D. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.564627 · Cited by 8
Engineering optimal vaccination strategies: effects of physical properties of the delivery system on functions
Zhu, G., Yang, Y., & Sun, T. (2022) · Biomaterials Science · doi:10.1039/d2bm00011c · Cited by 8
Development and evaluation of PlasmoPod: A cartridge-based nucleic acid amplification test for rapid malaria diagnosis and surveillance
Bechtold, P., Wagner, P., Hosch, S., Gregorini, M., Stark, W. J., Gody, J. C., Kodia-Lenguetama, E. R., Pagonendji, M. S., Donfack, O. T., Phiri, W. P., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001516 · Cited by 8
Getting ready for malaria elimination: a check list of critical issues to consider
González-Silva, M., Bassat, Q., & Alonso, P. L. (2014) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-0276140205 · Cited by 8
Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: A randomized, double-blind, lot-to-lot consistency trial
Umeh, R. E., Oguche, S., Oguonu, T., Pitmang, S., Shu, E. N., Onyia, J. T., Daniyam, C. A., Shwe, D. D., Ahmad, A., Jongert, E., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.067 · Cited by 8

Authors: The RTS, S. C. T. P.
Affiliations: Program for Appropriate Technology in Health (US)
Corresponding author: The RTS,S Clinical Trials Partnership
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-12-13
Volume: 367
Issue: 24
Pages: 2284-2295
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1208394
PMC: PMC10915853
OpenAlex: W2244674613
Cited by: 752
References: 31
Citations by year: 2026: 18 · 2025: 29 · 2024: 35 · 2023: 38 · 2022: 36 · 2021: 42 · 2020: 45 · 2019: 47 · 2018: 40 · 2017: 58 · 2016: 67 · 2015: 74 · 2014: 111 · 2013: 103 · 2012: 7
FWCI: 91.09
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: New England Journal of Medicine (publishedVersion, other-oa)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
IHI Repository (acceptedVersion)
PubMed Central (acceptedVersion)
LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders: Bill and Melinda Gates Foundation
GlaxoSmithKline
Wellcome Trust (092654)
National Institutes of Health (CC999999)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
Keywords: RTS,S/AS01, malaria vaccine, infants, vaccine efficacy, clinical malaria, severe malaria, circumsporozoite protein, co-administration, immunogenicity, vaccine safety, Plasmodium falciparum, African infants, malaria prevention, vaccine adverse events
MeSH terms: Africa, Female, Humans, Immunization Schedule, Infant, Male, Plasmodium falciparum, Vaccines, Synthetic, Incidence, Proportional Hazards Models, Malaria, Falciparum, Treatment Outcome, Malaria Vaccines, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks